Table 1 Patient demographics and disease characteristics
No. of patients | % | |
|---|---|---|
Age, years | ||
Median | 66 | |
Range | 39–82 | |
ECOG performance status | ||
0 | 25 | 78.1 |
1 | 5 | 15.6 |
2 | 2 | 6.3 |
(Neo-)adjuvant chemotherapy | 22 | 68.7 |
Anthracycline | 7 | 21.9 |
Taxane | 2 | 6.3 |
Anthracycline + taxan | 11 | 34.4 |
Oral 5FU | 1 | 3.1 |
CMF | 1 | 3.1 |
Adjuvant endocrine therapy | 14 | 43.7 |
Prior endocrine therapy for advanced disease | 15 | 46.9 |
No. of prior chemotherapy regimens for advanced disease | ||
0 | 22 | 68.8 |
1 | 10 | 31.3 |
Taxan | 5 | 15.6 |
Oral 5FU (capecitabine or S-1) | 5 | 15.6 |
ER-postive | 19 | 59.4 |
PgR-positive | 18 | 56.3 |
HER2-positive | 1 | 3.1 |
Triple negatve | 11 | 33.3 |
Metastatic site | ||
Liver | 14 | 43.8 |
Lung | 14 | 43.8 |
Brain | 0 | 0 |
Bone | 13 | 40.6 |
Skin | 8 | 25 |
Other | 14 | 43.8 |
No of organs involved | ||
1 | 9 | 28.1 |
2 | 13 | 40.6 |
3 | 5 | 15.6 |
4 | 5 | 15.6 |
Site of disease | ||
Viceral | 23 | 71.9 |